Trial Profile

Phase Ib Study of Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM): "The CyBorD-DARA Study"

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms CyBorD-Dara

01 Nov 2022 Results investigating the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma published in the Clinical Lymphoma, Myeloma & Leukemia
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
04 Dec 2018 Results assessing safety and efficacy of Daratumumab in Multiple myeloma patients presented at the 60th Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com